

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zai Lab Limited

再鼎醫藥有限公司 *

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 9688)

VOLUNTARY ANNOUNCEMENT

CHANGE OF COMPOSITION OF COMMERCIAL COMMITTEE

The board of directors (the “**Board**”) of Zai Lab Limited (the “**Company**”) is pleased to announce that, following the establishment of the Commercial Committee of the Board (the “**Commercial Committee**”) on January 7, 2023 being chaired by Mr. Michel Vounatsos, an independent director of the Company, Mr. William Lis and Mr. Leon O. Moulder, Jr., independent directors of the Company, were appointed as members of the Commercial Committee with effect from January 13, 2023.

By order of the Board

Zai Lab Limited

Samantha Du

Director, Chairperson and Chief Executive Officer

Hong Kong, January 18, 2023

As at the date of this announcement, the board of directors of the Company comprises Dr. Samantha Du as a director, and Dr. Kai-Xian Chen, Dr. John Diekman, Ms. Nisa Leung, Mr. William Lis, Mr. Leon O. Moulder, Jr., Mr. Peter Wirth, Mr. Scott W. Morrison, Richard Gaynor, M.D. and Mr. Michel Vounatsos as independent directors.

* *For identification only*